Literature DB >> 28848926

Journal Club: Inhaled Corticosteroids- Refining Our Understanding of Their Role in Maintenance Treatment for COPD.

Ron Balkissoon1.   

Abstract

Entities:  

Keywords:  chronic obstructive pulmonary disease; copd; inhaled corticosteroids

Year:  2017        PMID： 28848926      PMCID： PMC5559116          DOI： 10.15326/jcopdf.4.2.2017.0143

Source DB:  PubMed          Journal:  Chronic Obstr Pulm Dis        ISSN： 2372-952X


× No keyword cloud information.
  16 in total

1.  Discontinuation of Inhaled Corticosteroids in COPD and the Risk Reduction of Pneumonia.

Authors:  Samy Suissa; Janie Coulombe; Pierre Ernst
Journal:  Chest       Date:  2015-11       Impact factor: 9.410

2.  Eosinophilia, Frequent Exacerbations, and Steroid Response in Chronic Obstructive Pulmonary Disease.

Authors:  Peter M A Calverley; Kay Tetzlaff; Claus Vogelmeier; Leonardo M Fabbri; Helgo Magnussen; Emiel F M Wouters; William Mezzanotte; Bernd Disse; Helen Finnigan; Guus Asijee; Christoph Hallmann; Henrik Watz
Journal:  Am J Respir Crit Care Med       Date:  2017-11-01       Impact factor: 21.405

3.  Inhaled fluticasone and budesonide increased the risk of serious pneumonia in COPD.

Authors:  Patrick White
Journal:  Evid Based Med       Date:  2014-02-14

4.  Reported pneumonia in patients with COPD: findings from the INSPIRE study.

Authors:  Peter M A Calverley; Robert A Stockley; Terence A R Seemungal; Gerry Hagan; Lisa R Willits; John H Riley; Jadwiga A Wedzicha
Journal:  Chest       Date:  2010-06-24       Impact factor: 9.410

5.  Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD.

Authors:  Courtney Crim; Mark T Dransfield; Jean Bourbeau; Paul W Jones; Nicola A Hanania; Donald A Mahler; Jørgen Vestbo; Andrew Wachtel; Fernando J Martinez; Frank Barnhart; Sally Lettis; Peter M A Calverley
Journal:  Ann Am Thorac Soc       Date:  2015-01

6.  Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results.

Authors:  C Crim; P M A Calverley; J A Anderson; B Celli; G T Ferguson; C Jenkins; P W Jones; L R Willits; J C Yates; J Vestbo
Journal:  Eur Respir J       Date:  2009-05-14       Impact factor: 16.671

7.  A 4-year trial of tiotropium in chronic obstructive pulmonary disease.

Authors:  Donald P Tashkin; Bartolome Celli; Stephen Senn; Deborah Burkhart; Steven Kesten; Shailendra Menjoge; Marc Decramer
Journal:  N Engl J Med       Date:  2008-10-05       Impact factor: 91.245

8.  Withdrawal of inhaled glucocorticoids and exacerbations of COPD.

Authors:  Helgo Magnussen; Bernd Disse; Roberto Rodriguez-Roisin; Anne Kirsten; Henrik Watz; Kay Tetzlaff; Lesley Towse; Helen Finnigan; Ronald Dahl; Marc Decramer; Pascal Chanez; Emiel F M Wouters; Peter M A Calverley
Journal:  N Engl J Med       Date:  2014-09-08       Impact factor: 91.245

9.  Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.

Authors:  Claus F Vogelmeier; Gerard J Criner; Fernando J Martínez; Antonio Anzueto; Peter J Barnes; Jean Bourbeau; Bartolome R Celli; Rongchang Chen; Marc Decramer; Leonardo M Fabbri; Peter Frith; David M G Halpin; M Victorina López Varela; Masaharu Nishimura; Nicolás Roche; Roberto Rodríguez-Roisin; Don D Sin; Dave Singh; Robert Stockley; Jørgen Vestbo; Jadwiga A Wedzicha; Alvar Agustí
Journal:  Arch Bronconeumol       Date:  2017-03-06       Impact factor: 4.872

10.  Inhaled corticosteroids in COPD and the risk of serious pneumonia.

Authors:  Samy Suissa; Valérie Patenaude; Francesco Lapi; Pierre Ernst
Journal:  Thorax       Date:  2013-11       Impact factor: 9.139
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.